Fluconazole-malonic acid (1/1).

Co-crystallizaton of the anti-fungal drug fluconazole [2-(2,4-difluoro-phen-yl)-1,3-bis-(1H-1,2,4-triazol-1-yl)propan-2-ol] with malonic acid in acetonitrile solution resulted in the formation of the title 1:1 co-crystal, C13H12F2N6O·C3H4O4. The geometry around the central fluconazole atom is distorted tetrahedral. The dihedral angles between the triazole rings and the fluorinated phenyl ring are 30.64 (7) and 61.91 (5)°. In the crystal, the basic packing motif may be envisioned as a cyclic aggregate formed of two fluconazole mol-ecules linked by two malonic acid mol-ecules through O-H⋯N and O-H⋯O hydrogen bonds. Such aggregates are further connected into (001) layers by further O-H⋯N hydrogen bonds. The structure also features weak non-classical C-H⋯O and C-H⋯N inter-actions.

A 1:1 cocrystal of fluconazole with salicylic acid.

The interaction of the antifungal pharmaceutical agent fluconazole with salicylic acid in acetonitrile solution yields the 1:1 cocrystal 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol-2-hydroxybenzoic acid (1/1), C(13)H(12)F(2)N(6)O·C(7)H(6)O(3). The asymmetric unit consists of one molecule of fluconazole and one molecule of salicylic acid, both in their neutral forms. Both crystal agents form head-to-tail hydrogen-bonded dimers, which are further connected into hydrogen-bonded extended zigzag tapes propagating along the ac diagonal.